<DOC>
	<DOCNO>NCT00524069</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , gemcitabine capecitabine , work different way stop growth tumor cell , either kill cell stop dividing . Monoclonal antibody , bevacizumab , block tumor growth different way . Some block ability tumor cell grow spread . Others find tumor cell help kill carry tumor-killing substance . Bevacizumab may also stop growth tumor cell block blood flow tumor . Giving gemcitabine capecitabine together bevacizumab may kill tumor cell . PURPOSE : This clinical trial study side effect well give gemcitabine capecitabine together bevacizumab work treat patient pancreatic cancer remove surgery .</brief_summary>
	<brief_title>Gemcitabine , Capecitabine , Bevacizumab Treating Patients With Pancreatic Cancer That Can Be Removed By Surgery</brief_title>
	<detailed_description>OBJECTIVES : Primary - To determine feasibility safety bevacizumab-based neoadjuvant adjuvant therapy patient resectable pancreatic adenocarcinoma . - To determine proportion patient margin-positive resection pancreatic resection . Secondary - To estimate overall survival patient treat regimen . - To assess time recurrence patient treat regimen . - To measure change number circulate endothelial precursor cell ( CEC ) VEGF expression CEC baseline start neoadjuvant therapy examine relationship response , time recurrence , survival . - To assess utility dynamic contrast-enhanced spiral CT scan surrogate endpoint antiangiogenic therapy . OUTLINE : This multicenter study . - Neoadjuvant therapy : Patients receive gemcitabine IV 30 minute day 1 8 ; oral capecitabine twice daily day 1-14 ; bevacizumab* IV 30-90 minute day 1 . Treatment repeat every 3 week 3 course absence disease progression unacceptable toxicity . NOTE : *Patients receive bevacizumab course 1 2 . - Surgical resection : Within 6-8 week last dose bevacizumab , patient undergo surgical resection pancreatic tumor . - Adjuvant therapy : Beginning 6-10 week surgery , patient receive 6 additional course gemcitabine , capecitabine , bevacizumab neoadjuvant therapy . Patients undergo blood sample collection baseline periodically study biomarker correlative study . Samples analyze flow cytometry measure level circulate endothelial precursor cell VEGF marker angiogenesis . Patients also undergo dynamic contrast-enhanced ( DCE ) spiral CT scan abdomen . DCE-CT image study perform baseline completion neoadjuvant therapy ( 1-2 week prior surgical resection ) ass change tumor blood flow , blood volume , tumor vasculature . After completion study therapy , patient follow periodically least 5 year .</detailed_description>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm pancreatic adenocarcinoma Resectable disease ( i.e. , stage I II disease ) No unresectable ( i.e. , locally advance ) disease No tumor invasion stomach duodenum No CNS , brain , systemic metastasis PATIENT CHARACTERISTICS : ECOG performance status 01 WBC &gt; 3,000/μL ANC &gt; 1,500/μL Platelet count &gt; 100,000/μL Total bilirubin &lt; 2 mg/dL AST ALT &lt; 2.5 time upper limit normal ( ULN ) Creatinine &lt; 1.5 mg/dL Creatinine clearance ≥ 50 mL/min Urine protein : creatinine ratio &lt; 1.0 Hemoglobin ≥ 9 g/dL ( transfusion , epoetin alfa , darbepoetin allow ) INR &lt; 1.5 time ULN ( except patient receive fulldose warfarin ) Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No uncontrolled hypertension No unstable angina No New York Heart Association class IIIV congestive heart failure No myocardial infarction stroke within past 6 month No clinically significant peripheral vascular disease No evidence bleed diathesis coagulopathy No significant traumatic injury within past 28 day No abdominal fistula , gastrointestinal perforation , intraabdominal abscess within past 6 month No esophageal gastric varix No serious nonhealing wound , ulcer , bone fracture PRIOR CONCURRENT THERAPY : No prior therapy pancreatic cancer More 4 week since prior concurrent participation another experimental drug study More 28 day since prior major surgical procedure open biopsy More 7 day since prior minor surgical procedure ( e.g. , fineneedle aspiration core biopsy )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>stage I pancreatic cancer</keyword>
	<keyword>stage II pancreatic cancer</keyword>
	<keyword>adenocarcinoma pancreas</keyword>
</DOC>